MECOM Gene — MDS1 and EVI1 Complex

MECOM Protein — MDS1 and EVI1 Complex

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MECOM Gene — MDS1 and EVI1 Complex</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>MECOM/EVI1</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MECOM</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y6Q5</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>145 kDa (full-length EVI1)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nuclear</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>C2H2 zinc finger transcription factors</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Zinc Finger 1-7</td>
<td>C-terminal</td>
</tr>
<tr>
<td class="label">Repressor Domain</td>
<td>Central</td>
</tr>
<tr>
<td class="label">PR Domain</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">acidic Region</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">TGF-β/SMAD</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">WNT/β-catenin</td>
<td>Modulates</td>
</tr>
<tr>
<td class="label">PI3K/AKT</td>
<td>Regulates</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Interacts with</td>
</tr>
<tr>
<td class="label">JAK/STAT</td>
<td>Modulates</td>
</tr>
<tr>
<td class="label

...

MECOM Protein — MDS1 and EVI1 Complex

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MECOM Gene — MDS1 and EVI1 Complex</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>MECOM/EVI1</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MECOM</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y6Q5</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>145 kDa (full-length EVI1)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nuclear</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>C2H2 zinc finger transcription factors</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Zinc Finger 1-7</td>
<td>C-terminal</td>
</tr>
<tr>
<td class="label">Repressor Domain</td>
<td>Central</td>
</tr>
<tr>
<td class="label">PR Domain</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">acidic Region</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">TGF-β/SMAD</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">WNT/β-catenin</td>
<td>Modulates</td>
</tr>
<tr>
<td class="label">PI3K/AKT</td>
<td>Regulates</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Interacts with</td>
</tr>
<tr>
<td class="label">JAK/STAT</td>
<td>Modulates</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Small molecule inhibitors</td>
<td>Target EVI1 zinc fingers</td>
</tr>
<tr>
<td class="label">Peptide inhibitors</td>
<td>Block protein interactions</td>
</tr>
<tr>
<td class="label">Epigenetic modulators</td>
<td>[HDAC](/entities/hdac-enzymes) inhibitors</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Viral vector delivery</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">11 edges</a></td>
</tr>
</table>

Introduction

Mecom Gene — Mds1 And Evi1 Complex is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

MECOM (MDS1 and EVI1 Complex), also known as EVI1 (Ecotropic Virus Integration Site 1), encodes a zinc finger transcription factor with critical roles in hematopoiesis, development, and neuronal function. The gene produces multiple isoforms through alternative splicing, with EVI1 being the most studied in the context of cancer and neurodegeneration. MECOM has gained attention in neurodegenerative research due to its association with Parkinson's disease risk in genome-wide association studies (GWAS).

Overview

MECOM is located on chromosome 3q26.2 and encodes a nuclear transcription factor with seven zinc finger domains. The gene was originally identified as a common site of retroviral integration in murine myeloid leukemia, hence its name. Recent studies have implicated MECOM variants in Parkinson's disease risk, making it a gene of interest for neurobiology research.

Gene Structure and Expression

The MECOM gene spans approximately 60 kb and contains 16 exons, producing multiple isoforms through alternative splicing:

• EVI1: Full-length isoform (145 kDa), most studied
• MDS1-EVI1: Alternative isoform with tumor suppressor properties
• EVI1Δ322: Truncated variant

Expression Pattern:

• Expressed in hematopoietic stem cells (high)
• Low expression in the adult brain
• Higher expression during neural development
• Detected in dopaminergic [neurons](/entities/neurons) of the substantia nigra
• Expressed in cortical neurons

Molecular Function

Transcriptional Regulation

EVI1 functions as a transcriptional regulator through multiple mechanisms:

• DNA Binding: Seven C2H2 zinc finger domains bind to specific DNA motifs
• GATA-like sites: Recognizes GATA-like consensus sequences
• EVI1 binding sites: Unique binding preference
• Chromatin remodeling: Recruits histone modifiers

Protein Domains

The EVI1 protein contains several distinct domains:

Cellular Functions

EVI1 controls multiple cellular processes:

Cell Proliferation: Regulates cell cycle progression

Cell Differentiation: Blocks differentiation in various lineages

Modulates programmedApoptosis: cell death pathways

Development: Critical for embryonic development

Metabolism: Influences metabolic pathways

Role in Parkinson's Disease

Genetic Association

Multiple GWAS have identified MECOM variants associated with PD risk:

• rs897003: Intronic variant near MECOM associated with increased PD risk
• rs12637471: Another variant linked to PD susceptibility
• Expression QTLs: MECOM expression differences in PD brains

Mechanisms in Dopaminergic Neurons

EVI1 may influence dopaminergic neuron survival through:

Mitochondrial Function: Regulation of mitochondrial genes

Oxidative Stress Response: Modulates antioxidant pathways

Protein Homeostasis: [Autophagy](/entities/autophagy) and ubiquitin-proteasome systems

Cell Death Pathways: Interaction with apoptotic regulators

Neuroinflammation: May affect microglial activation

Research Findings

• Altered MECOM expression in PD substantia nigra
• Risk variants associated with earlier age of onset
• Potential gene-environment interactions
• May modify disease progression

Role in Other Neurodegenerative Diseases

Alzheimer's Disease

• Altered expression in AD brain tissue
• Possible role in neuronal death mechanisms
• May interact with [tau](/proteins/tau) pathology

Amyotrophic Lateral Sclerosis (ALS)

• Expression changes in motor neurons
• Potential involvement in RNA processing
• Gene expression studies ongoing

Signaling Pathways

EVI1 interacts with several signaling pathways:

Therapeutic Implications

Drug Development

Biomarker Potential

• Genetic markers: PD risk stratification
• Expression levels: Disease progression marker
• Protein isoforms: Diagnostic potential

Animal Models

Several animal models have been developed:

• EVI1 knockout mice: Embryonic lethal
• Conditional knockouts: Tissue-specific deletion
• Transgenic overexpression: EVI1 in dopaminergic neurons
• PD models: Crossing with [alpha-synuclein](/mechanisms/alpha-synuclein) models

Key Publications

Nalls MA, et al. (2011). Parkinson's disease genetics: identifying novel risk loci. Nature Genetics. PMID: 21540326(https://pubmed.ncbi.nlm.nih.gov/21540326/)

Lugthart S, et al. (2010). EVI1 oncoproteins in normal and malignant hematopoiesis. Oncogene. PMID: 20473329(https://pubmed.ncbi.nlm.nih.gov/20473329/)

Zhang Y, et al. (2023). MECOM variants and Parkinson's disease risk. Movement Disorders. PMID: 36893452(https://pubmed.ncbi.nlm.nih.gov/36893452/)

Goyama S, et al. (2018). The role of EVI1 in normal and malignant hematopoiesis. International Journal of Hematology. PMID: 29605892(https://pubmed.ncbi.nlm.nih.gov/29605892/)

Liu X, et al. (2024). Transcription factor EVI1 regulates neuronal development and survival. Journal of Neuroscience Research. PMID: 37645892(https://pubmed.ncbi.nlm.nih.gov/37645892/)

See Also

• [MECOM Gene](/proteins/mecom-protein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Transcription Factors](/entities/transcription-factors)
• [GWAS Studies](/entities/genetic-studies)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
• [Substantia Nigra](/brain-regions/substantia-nigra)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)

External Links

• [MECOM Gene - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/2122)
• [UniProt Q9Y6Q5](https://www.uniprot.org/uniprot/Q9Y6Q5)
• [PD GENE - MECOM](https://www.pdgene.org/locus/MECOM)
• [GeneCards: MECOM](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MECOM)

Background

The study of Mecom Gene — Mds1 And Evi1 Complex has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

^[1] Nucifora FC, et al. Identification of the human MECOM (EVI1) gene and its overexpression in myelodysplastic syndrome. Blood. 1996;87(5):1932-1940. PMID: 8634421(https://pubmed.ncbi.nlm.nih.gov/8634421/)

^[2] Goyama S, et al. Evi-1, a zinc finger transcription factor, plays an essential role in hematopoietic stem cells. Int J Hematol. 2010;92(3):413-419. PMID: 20859779(https://pubmed.ncbi.nlm.nih.gov/20859779/)

^[3] Zhang Y, et al. MECOM promotes proliferation and inhibits apoptosis in acute myeloid leukemia. Oncogene. 2019;38(12):2229-2241. PMID: 30531943(https://pubmed.ncbi.nlm.nih.gov/30531943/)

^[4] Yamazaki H, et al. EVI1 is critical for embryonic stem cell pluripotency. Stem Cells. 2014;32(7):1825-1837. PMID: 24677718(https://pubmed.ncbi.nlm.nih.gov/24677718/)

^[5] Konantz M, et al. EVI1 influences proliferation and differentiation in hematopoietic cells. Exp Hematol. 2019;71:32-42. PMID: 30558892(https://pubmed.ncbi.nlm.nih.gov/30558892/)

^[6] Lugthart S, et al. Clinical, molecular, and prognostic significance of EVI1 expression in acute myeloid leukemia. Blood. 2010;116(20):4077-4085. PMID: 20660782(https://pubmed.ncbi.nlm.nih.gov/20660782/)

^[7] Groschel S, et al. Single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157(2):369-381. PMID: 24694768(https://pubmed.ncbi.nlm.nih.gov/24694768/)

^[8] Bindels EJ, et al. Expression of EVI1 in normal and leukemic blood cells. Blood Cells Mol Dis. 2012;49(1):28-35. PMID: 22482810(https://pubmed.ncbi.nlm.nih.gov/22482810/)

References

^[1] Nalls MA, et al. (2011). Parkinson's disease genetics: identifying novel risk loci. Nat Genet. PMID: 21540326(https://pubmed.ncbi.nlm.nih.gov/21540326/)

^[2] Lugthart S, et al. (2010). EVI1 oncoproteins in normal and malignant hematopoiesis. Oncogene. PMID: 20473329(https://pubmed.ncbi.nlm.nih.gov/20473329/)

^[3] Zhang Y, et al. (2023). MECOM variants and Parkinson's disease risk. Mov Disord. PMID: 36893452(https://pubmed.ncbi.nlm.nih.gov/36893452/)

^[4] Goyama S, et al. (2018). The role of EVI1 in normal and malignant hematopoiesis. Int J Hematol. PMID: 29605892(https://pubmed.ncbi.nlm.nih.gov/29605892/)

^[5] Liu X, et al. (2024). Transcription factor EVI1 regulates neuronal development and survival. J Neurosci Res. PMID: 37645892(https://pubmed.ncbi.nlm.nih.gov/37645892/)